Medical technology

AI-based Surgical Robots Market Size To Reach $17.2 Billion By 2028: Grand View Research, Inc.

Retrieved on: 
Wednesday, July 7, 2021

SAN FRANCISCO, July 7, 2021 /PRNewswire/ -- The global AI-based surgical robots market size is expected to reach USD 17.2 billion by 2028, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, July 7, 2021 /PRNewswire/ -- The global AI-based surgical robots market size is expected to reach USD 17.2 billion by 2028, according to a new report by Grand View Research, Inc.
  • Increased efficiency and success rate provided by robotic surgeries are boosting the growth of the market.
  • In addition, the shift in preference for minimally invasive surgeries by patients over traditional methods is further bolstering the growth.
  • Grand View Research has segmented the global AI-based surgical robots market based on product, application, and region:
    AI-based Surgical Robots Product Outlook (Revenue, USD Million, 2016 - 2028)
    AI-based Surgical Robots Application Outlook (Revenue, USD Million, 2016 - 2028)

Integrity Implants and Fusion Robotics Merge to Form Accelus

Retrieved on: 
Tuesday, July 6, 2021

Both Fusion Robotics and Integrity Implants have built enabling technology platforms that create a force multiplier for spinal care.

Key Points: 
  • Both Fusion Robotics and Integrity Implants have built enabling technology platforms that create a force multiplier for spinal care.
  • The combination of Fusion Robotics efficient, compact and scalable robot with Integrity Implants unique Adaptive Geometry implants will enable the rapid acceleration of MIS adoption.
  • Integrity Implants also holds FDA clearances for its LineSider Spinal System, FlareHawk TiHawkInterbody Fusion System and Toro-L Interbody Fusion System.
  • The companys Executive Management Team will consist of leaders from both Integrity Implants and Fusion Robotics, who bring decades of experience and leadership across spine, navigation and surgical robotics.

Insightec Announces Samsung Medical Center Is Joining Focused Ultrasound Community

Retrieved on: 
Monday, July 5, 2021

"Focused Ultrasound enables performing precise, minimally invasive treatments," Prof. Jung Il Lee, Professor, Department of Neurosurgery, Samsung Medical Center explains.

Key Points: 
  • "Focused Ultrasound enables performing precise, minimally invasive treatments," Prof. Jung Il Lee, Professor, Department of Neurosurgery, Samsung Medical Center explains.
  • There are 81 leading medical centers globally that have established Focused Ultrasound programs with Exablate Neuro.
  • Insightec is partnering with Huons, a manufacturer of pharmaceutical products and distributor of medical solutions, to expand Focused Ultrasound programs in the Korean market.
  • "Exablate," and "Exablate Neuro," as well as the "INSIGHTEC" logo, whether standing alone or in connection with the word " Insightec", are protected trademarks of Insightec.

Sentrx™ Animal Care, Inc. Announces Manufacturing Facility Expansion to Accommodate Accelerated Growth

Retrieved on: 
Thursday, July 1, 2021

On May 20th, 2021 Sentrx Animal Care held a ribbon cutting ceremony to celebrate the completion and opening of its brand new 22,000 square foot manufacturing facility in Salt Lake City, Utah.

Key Points: 
  • On May 20th, 2021 Sentrx Animal Care held a ribbon cutting ceremony to celebrate the completion and opening of its brand new 22,000 square foot manufacturing facility in Salt Lake City, Utah.
  • The expansion into this larger new facility represents a major milestone for the Salt Lake City based company.
  • Sentrx also completed ISO audits in April and maintains ISO 13485 certification in this new facility.
  • Sentrx runs a vertically integrated manufacturing operation, procuring only raw materials and components from third parties.

Align Technology Announces Recipients of Its Invisalign® ChangeMakers Program

The goal of Invisalign ChangeMakers is to celebrate and highlight teens making a positive impact in their communities.

Key Points: 
  • The goal of Invisalign ChangeMakers is to celebrate and highlight teens making a positive impact in their communities.
  • We congratulate the Invisalign ChangeMakers award recipients and look forward to celebrating these young leaders to recognize their community-focused accomplishments.
  • Align Technology designs, manufactures and offers the Invisalign system, the most advanced clear aligner system in the world, iTero intraoral scanners and services, and exocad CAD/CAM software.
  • For additional information about the Invisalign system or to find an Invisalign doctor in your area, please visit www.invisalign.com .

Global Mobile Imaging Services Markets 2021-2028 - Integration of Machine Learning and Advanced Computation With Medical Imaging - ResearchAndMarkets.com

Retrieved on: 
Monday, June 28, 2021

The publisher implies that the global mobile imaging services market is assessed to display growth at a CAGR of 4.62% over the assessed period 2021-2028.

Key Points: 
  • The publisher implies that the global mobile imaging services market is assessed to display growth at a CAGR of 4.62% over the assessed period 2021-2028.
  • Factors such as proactive government initiatives, growing occurrence of chronic disorders, and increasing geriatric population are key factors that add to the growth of the mobile imaging services market.
  • Several governments are taking initiatives to support hospitals and research organizations in developing advanced imaging services.
  • The Asia-Pacific region is estimated to become the fastest evolving region in the mobile imaging services market.

Senseonics Announces Presentation of PROMISE Data at the American Diabetes Association 81st Scientific Sessions

Retrieved on: 
Monday, June 28, 2021

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced further presentation of PROMISE Study data evaluating the next generation Eversense CGM System at the American Diabetes Association Virtual 81st Annual Scientific Sessions.

Key Points: 
  • Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced further presentation of PROMISE Study data evaluating the next generation Eversense CGM System at the American Diabetes Association Virtual 81st Annual Scientific Sessions.
  • The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions in the US.
  • The Eversense CGM System is a prescription device; patients should talk to their health care provider to learn more.
  • The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.

Second Sight Medical Products Announces Closing of Public Offering

Retrieved on: 
Friday, June 25, 2021

Second Sight Medical Products, Inc. (NASDAQ: EYES) (Second Sight or the Company), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the closing of its previously announced underwritten public offering of 11,500,000 shares of its common stock at a public offering price of $5.00 per share, which includes 1,500,000 shares sold upon full exercise of the underwriters option to purchase additional shares.

Key Points: 
  • Second Sight Medical Products, Inc. (NASDAQ: EYES) (Second Sight or the Company), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the closing of its previously announced underwritten public offering of 11,500,000 shares of its common stock at a public offering price of $5.00 per share, which includes 1,500,000 shares sold upon full exercise of the underwriters option to purchase additional shares.
  • The gross proceeds from the offering, including the exercise of the over-allotment option, were $57,500,000, before deducting underwriting discounts, commissions and other offering expenses.
  • The Company intends to use the net proceeds from the offering primarily for development of the Orion device and general corporate purposes.
  • About Second Sight Medical Products, Inc.
    Second Sight Medical Products, Inc. (Nasdaq: EYES) develops implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals.

After 30 Years, the Company Responsible for Improving Millions of Titanium Implants Finally Has Something to Say

Retrieved on: 
Friday, June 25, 2021

Before hiring their new CEO, most of Himed's innovations flew under the radar, and all business was acquired through word of mouth.

Key Points: 
  • Before hiring their new CEO, most of Himed's innovations flew under the radar, and all business was acquired through word of mouth.
  • Millions of people are living with dental and medical implants that technology from Himed made possiblebut few know Himed's name.
  • This week, the full story will be told with the publication of the company's 30 year history titled Answering the Calls: 30 Years of Himed History .
  • Himed continues to make formative in-roads to healing technologies that greatly enhance outcomes for patients around the world.

Dexcom CGM Plays Starring Role at 81st Scientific Sessions of the American Diabetes Association

Retrieved on: 
Friday, June 25, 2021

DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today featured research and data presentations that will headline the 81st Scientific Sessions of the American Diabetes Association (ADA) virtual conference held June 25-29, 2021.

Key Points: 
  • DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today featured research and data presentations that will headline the 81st Scientific Sessions of the American Diabetes Association (ADA) virtual conference held June 25-29, 2021.
  • Poster 77-LB, A Retrospective Analysis of the Association between HbA1c and Continuous Glucose Monitor Use for U.S.
  • For more information about the 81st Scientific Sessions of the American Diabetes Association and to register to virtually attend the conference, visit professional.diabetes.org/scientific-sessions .
  • DexCom, Inc., headquartered in San Diego, CA, is dedicated to helping people better manage their diabetes by developing and marketing continuous glucose monitoring (CGM) products and tools for adult and pediatric patients.